EYEN News and Press, Eyenovia Inc. From 05/11/23

Announced FDA approval of Mydcombi™, a fixed dose combination of tropicamide and phenylephrine for mydriasis, the first FDA approved product to utilize the Optejet ® Received feedback from FDA on its Phase 3 Microline presbyopia candidate that provides a clear and effici...

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Eyenovia, Inc. (Nasdaq: EYEN) concerning the Company and its directors’ and officers’ possible violations of state laws. If you own Eyenovia stock, would like to learn more about these claims, o...

Represents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis Provides critical validation of key technology that is core to Eyenovia’s proprietary development programs as well as current and future partnerships NEW YORK, May 08, 2023 (G...

NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications, ...

2023-04-29 16:00:00 ET With the first trading day in May coming on Monday, many pharmaceutical companies will be hoping their returns fare better than they did in April. The iShares U.S. Pharmaceuticals ETF ( IHE ) returned a paltry 1.6% in April. The ETF's top two holdings are ...

NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive ...

2023-03-30 20:44:06 ET Eyenovia, Inc. (EYEN) Q4 2022 Results Conference Call March 30, 2023 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - CEO John Gandolfo - CFO Bren Kern - COO Presentation Operator Greetings, and welcom...

2023-03-30 16:23:05 ET Eyenovia press release ( NASDAQ: EYEN ): Q4 GAAP EPS of -$0.17 beats by $0.03 . For further details see: Eyenovia GAAP EPS of -$0.17 beats by $0.03

Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023 Announced positive results from Microline Phase 3 program as a potential treatment for presbyopia and received feedback from the FDA outlining a clear path forward for the program ...

NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indica...